The measured tesamorelin before and after is a 15.2% drop in visceral fat over 26 weeks, against a 5.0% gain on placebo. It wasn't a photo. It was a CT scan in a randomized trial, and the change it found is smaller than you'd guess from an image search.
The measured tesamorelin before and after is a 15.2% drop in visceral fat over 26 weeks, against a 5.0% gain on placebo. That came from a randomized trial of 412 adults with HIV-related fat accumulation, dosed daily for six months. The fat returned when the drug stopped. Nothing in the trial measured how anyone looked.
The trial that measured it
Falutz and colleagues randomized 412 adults with HIV and abdominal fat accumulation to 2 mg of tesamorelin daily or matching placebo for 26 weeks. The primary endpoint was the percent change in visceral adipose tissue on CT — the deep fat around the organs, not the fat under the skin.
Visceral fat fell 15.2% on the drug and rose 5.0% on placebo. Triglycerides fell 50 mg per deciliter and rose 9 mg per deciliter. IGF-1 rose 81.0%, confirming the compound did what a GHRH analog is supposed to do.
The measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group.
Falutz et al., New England Journal of Medicine, 2007That paired comparison is what a before and after means when somebody measures it: treated group against placebo group, same weeks, same instrument, same reader. The placebo arm is the half no photograph has.
Two Phase III trials of this design carried the compound to FDA approval. Our HIV lipodystrophy review covers the approval record in full.
What a 15% change looks like from the outside
A percentage of an internal fat depot is hard to picture, so it helps to see the same effect in other units. In a 2024 substudy of 38 patients on modern integrase-inhibitor regimens, median visceral fat fell 25 cm² on tesamorelin and rose 14 cm² on placebo.
In a 2025 open-label trial of 73 people, waists in the tesamorelin group shrank by a median of 2.7 cm more than in the standard-of-care group. That's about an inch of waistline, after six months of daily injections. It's a real change, and a modest one.
Six months of daily dosing bought roughly an inch at the waist in the population studied. If a photo pair shows you more than that, it's showing something else as well: training, calorie restriction, weight loss, posture, or the camera.
The response wasn't uniform either. In the two completed placebo-controlled trials, a clinical response meant a visceral fat drop of at least 8%, and roughly 70% of treated participants reached it.
Close to a third didn't. A photograph is one draw from that distribution, chosen by someone with a reason to pick a good one.
Tesamorelin
The 44-amino-acid GHRH analog used across the Phase III trials cited here. Research use only, supplied with a batch-matched certificate of analysis.
What happened after the after
The 26-week trial ran a 26-week extension, with patients re-randomized to continue or switch. Those who stayed on tesamorelin held the effect. Visceral fat was down 18% at 52 weeks, triglycerides were down 51 mg per deciliter, and adverse events in the second half resembled the first.
Then comes the sentence that matters most to anyone looking at a transformation image.
Though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment.
Falutz et al., AIDS, 2008Visceral fat reaccumulated once dosing stopped. A before-and-after pair is a snapshot taken inside a treatment window. The trial tells you what the third photograph looks like, and nobody posts the third photograph.
That's the single most useful thing we can hand you from this literature. The effect is real, and it's rented.
What the trials did not show
- Subcutaneous fat. The effect was selective for the visceral depot. The fat a photograph mostly shows was not the endpoint and did not fall with it.
- Muscle or strength. No lean-mass, performance or recovery endpoint appeared in the pivotal program. IGF-1 rose by 81%; nobody measured what that did to anyone's training.
- Cognition. A 2025 randomized trial did test it in 73 people. Waist circumference fell; neurocognitive scores did not separate from the comparison group.
- People without HIV. Every participant in the pivotal trials had HIV and antiretroviral-associated fat accumulation. No published trial has measured what tesamorelin does to body composition outside that population.
While tesamorelin reduced WC, the cognitive benefits did not significantly differ between groups.
Ellis et al., Journal of Infectious Diseases, 2025Liver fat is the one extra endpoint with a hard readout. A 12-month randomized trial in 61 people with HIV and fatty liver found hepatic fat fraction fell 4.1 points further than placebo, a 37% relative reduction.
In that trial, 35% of the treated group dropped below the 5% liver-fat threshold, against 4% on placebo. Fat quality changed too. CT density of both fat depots rose on treatment, independent of how much fat was lost.
Why the photos are not this trial
The gap between the trial and the image search isn't mainly about honesty. It's about population, dose and control.
- Different people. The trials enrolled adults with HIV-associated central fat accumulation. Most people posting photos are not in that group, and the fat compartment being targeted may not be the one they have.
- Different protocol. 2 mg subcutaneously, every day, for 26 to 52 weeks, supervised, with CT scans at both ends.
- No baseline. A photo has no scan, no placebo comparison and no verification that the vial contained what the label claimed.
- Everything else moved too. Diet, training, sleep, other compounds and simple weight loss all travel with the image and none of them are visible in it.
Side effects travel with the image too, and they're the one part of this record measured properly. Adverse events didn't differ significantly between groups in the pivotal trial, though more people withdrew from the tesamorelin arm because of one.
Our side-effect review covers the label-grade profile, including the glucose signal monitored in clinical use.
How to read any tesamorelin before-and-after
Four questions separate a measured result from a picture.
- Was anything instrumented? CT, MRI-derived fat fraction, DEXA or a tape measure at least. If the evidence is an image, it is not an endpoint.
- Compared with what? The placebo arms in these trials gained visceral fat. Without a comparison group, a change is not attributable to anything.
- Over how long? The measured effect took 26 weeks of daily dosing. A four-week transformation is not this drug's pharmacology.
- And afterward? The extension phase answered this. The effect does not outlive the treatment.
The published record here is unusually good for a peptide sold this way. Phase III trials, a label, an extension phase, and post-approval substudies on fat quality, liver fat and inflammatory markers.
We'd read it for what it says, which is quieter and more useful than what gets attributed to it. Our dosage guide covers the protocols the trials used. Our sermorelin before and after asks the same question of a compound with none of this evidence.
Tesamorelin
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The measured before and after is a scan. Visceral fat fell 15.2% over 26 weeks versus a 5.0% gain on placebo, in 412 adults.
- Sustained at 18% over 52 weeks of continued dosing — and reaccumulated after the drug stopped.
- In outward units the change is modest: a median 2.7 cm more waist reduction than standard of care over six months.
- About 70% of treated participants met the 8% visceral-fat response threshold. Roughly a third did not.
- Subcutaneous fat, lean mass and cognition were not improved. The effect is specific, and specific is not the same as dramatic.
What we're watching
The open question is whether tesamorelin's visceral-fat and liver-fat effects get tested outside HIV. Trials in metabolic liver disease would be the first controlled look at this compound in a general population.
They'd also be the first data anyone could honestly apply to the people searching for before-and-after photos. Until that reads out, every number on this page belongs to one clinical population.
Frequently asked questions
How much visceral fat did tesamorelin remove in the trial?
15.2% over 26 weeks on CT, compared with a 5.0% increase on placebo, in 412 adults with HIV-associated abdominal fat accumulation. Continued dosing held the reduction at 18% at 52 weeks.
How long does tesamorelin take to work?
The pivotal trials measured at 26 weeks of daily 2 mg dosing, with a 52-week extension. There is no published evidence of a meaningful body-composition change in the first few weeks; IGF-1 moves first, and fat follows over months.
Does the fat come back after stopping?
Yes. The 52-week extension reported that visceral fat reaccumulated after discontinuation, and the authors concluded the effects do not last beyond the duration of treatment.
Are tesamorelin before-and-after photos reliable?
No. The measured effect is on deep abdominal fat seen on a scan, worth roughly an inch of waist over six months. Photos have no baseline scan, no control group and no verification of dose or material, and they carry every diet and training change with them.
References
- Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/nejmoa072375
- Falutz, J., Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/qad.0b013e32830a5058
- Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1016/s1096-6374(10)70016-2
- Russo, S. C., Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
- Lake, J. E., La, K., Erlandson, K. M., et al. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35(9), 1395–1402. https://doi.org/10.1097/QAD.0000000000002897
- Ellis, R. J., Vaida, F., Hu, K., et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: A randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/s2352-3018(19)30338-8
- Fourman, L. T., Billingsley, J. M., Agyapong, G., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16). https://doi.org/10.1172/jci.insight.140134
- Stanley, T. L., Falutz, J., Mamputu, J. C., et al. (2011). Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS, 25(10), 1281–1288. https://doi.org/10.1097/qad.0b013e328347f3f1
- Rahman, F., McLaughlin, T., Mesquita, P., et al. (2022). Effect of tesamorelin in people with HIV with and without dorsocervical fat. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Sigalos, J. T., & Pastuszak, A. W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004